What is known and objective: Many critically ill patients are exposed to opioids and benzodiazepines at high doses for prolonged periods, and upon discontinuation of these drugs, they may be at risk for iatrogenic withdrawal. Although this syndrome was associated with worse outcomes in the critically ill, limited guidance exists regarding its evaluation, prevention and treatment. This systematic review examined the frequency, risk factors and symptomatology of iatrogenic withdrawal from opioids and/or benzodiazepines in critically ill neonates, children and adults. 
| WHAT IS K NOWN AND OBJEC TIVE
Opioids and sedatives are often used in the intensive care unit (ICU) to minimize patients' pain and discomfort, manage agitation and facilitate tolerance of invasive monitoring and life-support technology.
As per usual care in Canadian ICUs, most of mechanically ventilated patients receive opioids or sedatives (eg, benzodiazepines, propofol or dexmedetomidine) at least once during their stay.
1,2
Many patients are still exposed to opioids and benzodiazepines at high doses for prolonged periods despite guidelines promoting daily sedation interruption or sedation with lighter targets. [3] [4] [5] [6] [7] [8] [9] Upon discontinuation of these drugs, patients may be at risk for iatrogenic withdrawal. [10] [11] [12] [13] [14] In critically ill patients, this syndrome was associated with prolonged mechanical ventilation, paediatric intensive care unit (PICU) and hospital length of stay. 10, [15] [16] [17] [18] Recent data suggest that exposure to regular opioids or benzodiazepines as short as 3 days can induce withdrawal symptoms upon discontinuation. 15 Limited guidance exists regarding evaluation, prevention and treatment of withdrawal syndromes in critically ill patients. 3, 19 One systematic review on iatrogenic withdrawal risk factors in critically ill children was published and did not include adults. 20 A recent but limited scope literature review commented on the lack of assessment tools specifically for opioids in both critically ill children and adults hindering the appropriate management of withdrawal symptoms. 21 Therefore, we conducted a systematic review to examine the frequency, risk factors and symptomatology of iatrogenic withdrawal in critically ill paediatric and adult patients who received opioids and/ or benzodiazepines. Our goal was to rigorously establish the current state of knowledge in both populations and identify knowledge gaps to guide future research.
| ME THODS
This systematic review used the PRISMA guidelines for reporting and was registered in PROSPERO (registration number: CRD42016042746 were also summarized.
Withdrawal was considered as mixed in studies with patients receiving both opioids and benzodiazepines if no mention was made regarding sequential weaning. We planned to summarize withdrawal F I G U R E 1 Flow chart of study selection symptoms and their incidence based on the symptomatology described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 25 For simplification, the Finnegan score, Neonatal
Abstinence Score and Neonatal Abstinence Syndrome Score were reported as Neonatal Abstinence Syndrome Score (NASS).
Descriptive sensitivity analyses on the frequency of withdrawal were planned for paediatric vs adult populations and for studies before and after year 2000 to account for changes in practice given studies on daily sedation interruption. 5 
| RE SULTS

| Study selection
The database search retrieved 21 866 unique citations of which 21 713 were excluded based on titles and abstracts ( Figure 1 ). We assessed 153 full-text articles for eligibility and 34 studies were included.
| Study characteristics
Characteristics of included studies are reported in Tables S1 and S2 .
Regarding paediatric trials, we included one randomized controlled trial, seventeen prospective observational studies, four prospective tool validation studies and six retrospective observational studies Agents used for sedation and analgesia are reported in Tables S3   and S4 . For paediatric studies, limited information regarding treatments received by patients was found. Only five studies reported a specific protocol for titration of opioids and benzodiazepines. Eight trials did not report any specific agents used for sedation or analgesia during the study period (presumed usual care). When reported, the most frequently used opioids were fentanyl (N = 17) and morphine (N = 10), whereas the most frequently used benzodiazepines Two studies reported the use of continuous infusions of midazolam and one study reported the use of remifentanil continuous infusions.
Four trials did not report any specific agents preferably used for sedation or analgesia during the study period (presumed or stated that sedation and analgesia were as per usual care). Two studies mentioned that no standardized protocol was used for weaning opioids or benzodiazepines. Information regarding the use of other sedatives or coanalgesia was very limited.
Cumulative doses and duration of opioids and benzodiazepines are reported in Tables S5 and S6 . In both populations, cumulative dose and duration of use of opioids and benzodiazepines were inconsistently reported and greatly varied between studies.
| Evaluation and detection of withdrawal
Details regarding the evaluation of withdrawal are reported in Tables S7 and S8 . In paediatrics, most studies (N = 24) evaluated mixed withdrawal. Tools to evaluate withdrawal, including validated tools, were used in the majority of the paediatric studies (N = 24).
The most frequently used tools were the NASS (N = 9), The definition of withdrawal was more constant between studies using tools to evaluate withdrawal. In most studies using the WAT-1 (N = 6), withdrawal was defined as a score equal or more than three on one occasion.
In five out of six studies using the SOS, withdrawal was defined as a score equal or more than four. Withdrawal definition varied in studies using the NASS as two cut-off scores were used: In adults, all studies (N = 6) evaluated mixed withdrawal and none used validated tools to assess withdrawal. For withdrawal screening, scores or checklists of signs and symptoms were used in four studies, an adaptation of the DSM-5 criteria was used in one study and no tool or score was used one study. Withdrawal was retrospectively assessed by the investigators from chart review based on signs and symptoms in four studies. Two trials assessed withdrawal prospectively. In those studies, the evaluation of withdrawal was done once or twice daily by the investigators or an ICU fellow/staff, starting when the weaning of opioids and/or benzodiazepines began. Duration of withdrawal assessment varied from 3 days after weaning began, up to a maximum of 14 days depending on the study.
| Epidemiology
The frequency of iatrogenic withdrawal syndrome is reported
in Tables S3 and S4 . In paediatrics, mixed withdrawal was ob- 
| Symptomatology
We did not identify any adult or paediatric study reporting the incidence of signs and symptoms exclusive for opioid or benzodiazepine withdrawal. 33 Midazolam peak dose was a significant risk factor for withdrawal in one study (OR 1.4, P = 0.002), whereas another found a decreased risk of withdrawal for each day of morphine use before taper (OR 0.82, 95% CI 0.71-0.95). 15, 16 When compared to patient aged from 6 to 17.99 years old, patients aged from 2 weeks to 6 months old (OR 2.73, 95% CI 1.69-4.42) and patients aged from 6 months to 1.99 years (OR 1.55, 95% CI 1.03-2.34) were at a higher risk for withdrawal in one study. 33 The presence of cognitive impairment (OR 1.98, 95% CI 1.41-2.78) was also a significant risk factors for withdrawal in that study. 33 Finally, duration of extracorporeal membrane oxygenation (ECMO) (OR 2.4, 95% CI 1.1-5.3) and duration of ECMO of more than 5 days (OR 9.0, 95% CI 1.2-71.5) increased the risk of withdrawal in one study. 12 In adults, one study reported the daily dose of remifentanil (per mg/Kg/day) as an independent risk factor for withdrawal (OR 2.72, 95% CI 1.20-6.14). 50 In that study, heavier weight (per Kg) was a risk factor for withdrawal (OR 1.03, 95% CI 1.01-1.04), whereas older age (per year) was found to be protective (OR 0.97, 95% CI 0.95-0.99).
TA B L E 1 Significant risk factors for withdrawal reported in multivariable analysis in selected studies
| Risk of bias
Risk of bias scores are reported in Table S11 . or unclear (N = 1) risk of bias for the reference standard items. One other study was considered at unclear risk of bias for most items, except for patient selection and index test in the applicability concern section.
| Sensitivity analysis
We were unable to perform the descriptive sensitivity analysis on the frequency of withdrawal for studies done before and after year 2000 because of heterogeneity and inconsistent reporting in studies.
| D ISCUSS I ON
Iatrogenic withdrawal is more frequently described in the critically ill paediatric population and only few studies in critically ill adults exist.
Most studies were at high risk of bias and few well-designed studies were identified.
This syndrome appears to be frequent in both paediatric and adult critical care population receiving regular opioids and/or benzodiazepines for more than 72 hours. We found that in prospective studies, mixed withdrawal was observed in 16.7%-55% of adults and in 7.5%-100% of paediatric patients. This variability is mostly Most paediatric studies have used tools to evaluate withdrawal, although only a few used validated tools. Many studies used the NASS to evaluate withdrawal although it was never validated outside of the neonatal population. Even when using a validated tool, the range of the reported frequency of withdrawal in these studies remains wide.
We found no adult study using a validated tool to detect withdrawal.
Authors used various definitions, which are of questionable validity since they were never validated in an ICU setting. One study in adults used the modified DSM-5 criteria to detect withdrawal. 46 Although this is likely the gold standard for detection of withdrawal, these criteria were never validated in an ICU population.
No adult study has properly examined withdrawal nor developed a screening tool. In an attempt to use a validated paediatric tool in adults, one study evaluated the validity and reliability of the WAT-1 to assess withdrawal in an adult ICU population and showed poor sensitivity and specificity. 52 This is likely because iatrogenic withdrawal remains a difficult syndrome to evaluate properly in ICU patients. Many confounders (eg, multiple concomitant pathologies, exposure to multiple drugs, organ failure, drug interactions and delirium) interfere with its evaluation.
We found that symptomatology of iatrogenic withdrawal is not well described, especially in adults. No study describing the symptomatology of isolated iatrogenic opioid or benzodiazepine withdrawal in critical care patients was found, likely because those are often used concomitantly. A few studies, mostly in paediatrics, described the symptomatology of mixed withdra wal. 10, 13, 18, 26, 29, 34, 35, 37, 38, 41, 43 Frequently reported symptoms include insomnia, increased muscle tone, tachypnea, fever, sweating, diarrhoea, vomiting, yawning, sneezing, agitation, tremors and hallucinations.
Multiple trials examined potential risk factors for withdrawal in both the adult and paediatric population. The largest trial on risk factors for iatrogenic withdrawal in adults is currently unpublished. 50 The cumulative dose of opioids, as a risk factor, was consistently identified in both adult and paediatric literature. 10, 12, 13, 15, 18, 26, 27, 30, 33, 35, 37, 50 Similarly, the peak and cumulative doses of benzodiazepines were identified in multiple paediatric studies. 15, 16, 18, 26, 27, 37, 45 Duration of use of benzodiazepines and opioids was also reported frequently as risk factors for withdra wal. 10, 13, 15, 16, 18, 26, 27, 30, 33, 35, 50 Some suggest that regular exposure to these agents for 72 hours can induce withdrawal upon discontinuation. 15 Duration of ECMO was also a reported risk factor, although it is likely correlated to the duration of exposure to opioids and/or benzodiazepines.
12
The association between age and the risk of withdrawal seemed less constant between studies. The largest study on iatrogenic withdrawal risk factors in children found an independent association between younger age (2 weeks to 6 months old) and increased withdrawal, although no association was observed in another recent study. 15, 33 In very young patients, the risk for withdrawal is possibly variable over time given the immaturity of certain receptors (GABA, NMDA, opioid receptors) at birth and decreased metabolism and clearance of midazolam and morphine.
53
A systematic review was previously conducted on risk factors for iatrogenic withdrawal in the paediatric population. 20 The main risk factors reported in that study, namely the dose and duration of therapy with opioids and benzodiazepines, are consistent with our results. The current review brings novel information on the literature available on iatrogenic withdrawal, especially in adults. We identified a need to properly define the syndrome and its symptomatology, in both paediatric and adult patients. We also showed that there is a significant knowledge gap regarding iatrogenic withdrawal and a lack of adequately validated screening tools in adults.
Strengths of this study include an exhaustive search of the literature in the neonatal, paediatric and adult population, including grey literature and no language limitation. A risk of bias assessment was performed for each included study. Limits of this study include the presence of heterogeneity and variations in the definitions of withdrawal, preventing the authors from proceeding to a meta-analysis.
| WHAT IS NE W AND CON CLUS I ON
Iatrogenic withdrawal is a poorly defined and studied syndrome in the ICU population contributing to significant heterogeneity between studies regarding its frequency of observation. Although better described in paediatrics, studies in adults are lacking. The syndrome seems frequent in patients exposed to regular opioids and/or benzodiazepines for more than 3 days and those exposed to high doses of these agents. Additional knowledge gaps identified across all critically ill populations include the recognition of this syndrome through specific signs and symptoms of benzodiazepines and opioids withdrawal, the development of clinical bedside assessment tools, the identification of specific risks factors and ultimately the clinical impact of such syndrome on patient outcomes.
Larger studies are definitely required to improve our knowledge and understanding of withdrawal syndrome so we can better manage patients at risk and mitigate such iatrogenic complications.
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